Liver & Intrahepatic Bile Ducts
C22WHO Vol. 1
Digestive System
★ 8.0The Lancet
2026-08-22
Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial
In the randomised phase 3 TALENTOP trial (24 hospitals in China), patients with hepatocellular carcinoma and macrovascular invasion first received atezolizumab plus bevacizumab; 201 were then randomly assigned to liver resection (n=101) or continued systemic therapy (n=100). Median time to treatment…
Read the full story →★ 8.0Journal of Clinical Oncology
2026-06-01
Pemigatinib improves progression-free survival but not overall survival in first-line FGFR2-rearranged cholangiocarcinoma (phase 3 FIGHT-302)
In the randomized phase 3 FIGHT-302 trial, first-line pemigatinib extended median progression-free survival to 8.3 months versus 6.8 months with gemcitabine-cisplatin chemotherapy in advanced cholangiocarcinoma harbouring an FGFR2 rearrangement (HR 0.58; 95% CI 0.39-0.87; p=0.0078). Objective respon…
Read the full story →